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Clustered Regularly Interspaced Palindromic Repeats (CRISPR) were discovered within 
bacteria as a self-defense mechanism against invading viruses by using CRISPR associated (Cas) 
proteins to cleave viral double-stranded DNA (dsDNA). Since then the CRISPR-Cas9 system 
has rapidly evolved into one of the most efficient and effective means of genome editing. 
Utilizing a single-guide RNA complementary to the target genome DNA sequence, the Cas9 
enzyme from ​Streptococcus Pyogenes​ (SpyCas9) is able to recognize and cleave dsDNA. The 
goal of this research is to develop an in-vitro cleavage assay for the CRISPR-SpyCas9 system for 
further studies into the effects of RNA binding drugs such as Cisplatin and metal complexes on 
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I.) The Importance of Genome-Editing 
Genome editing is a relatively new field that utilizes different biological and/or chemical 
techniques to alter double-stranded DNA (dsDNA). The genome-editing field first began with 
gene studies in the late 19th century​1​ with mainly observational studies/ discoveries, for example, 
Gregor Mendel working with pea plants and mapping out different observations of inheritance 
between generations of the pea plants​2​. Around the middle of the twentieth century, however, 
breakthrough research discovered that mutations in genes could be created through radioactive 
and chemical treatments by Mueller​3​ and Auerbach et. al​4​, respectively. Both research teams 
found that these chemical and radioactive treatments led to random uncontrollable mutations 
within the genome of interest. This is a common issue throughout the history of genome editing 
as inaccuracies and imprecision can lead to serious consequences. A single alteration in an 
organism’s genome can create a series of genetic mutations and repercussions throughout an 
organism, and if that organism reproduces, pass those mutations onto the next generation​1​. It was 
not until the 1970s that a successful desired genomic change was achieved with yeast by cloning 
yeast cells with a chromosomal insertion by Rothstein​5​. Subsequent studies with an arsenal of 
methods for creating a targeted change in the genome led to the discovery of the Clustered 
Regularly Interspaced Palindromic Repeats (CRISPR) and the CRISPR-Cas9 system. The 
CRISPR-Cas9 system now dominates the genome-editing field due to its precision and accuracy 
in causing dsDNA breaks in virtually any genome.  
Prior to the introduction of the CRISPR-Cas9 system as a tool for genome editing, there 
were already two popular methods of genome editing: zinc-finger nucleases​6​ (ZFN) and 
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transcription activator-like effector nucleases​7​ (TALEN). Both of these genome editing tools 
were utilized to cause double-stranded breaks (DSBs) in DNA. ZFNs were first discovered while 
studying the restriction enzyme ​FokI​ and was determined to have binding and cleavage abilities 
that are independent of each other​8​. This independence was later realized that ZFNs utilize 
separate DNA cleavage and DNA binding domains where the restriction enzyme, ​FokI​, is only 
the DNA cleavage portion. The DNA binding domain of ZFNs is due to Zinc Fingers (ZFs) 
which are small proteins that utilize a Zinc atom to stabilize the folds within the protein. The 
DNA binding motif for ZFs is that they bind to 3 base pairs (bps) for each finger (usually three 
fingers per ZFN) which were confirmed through crystal structures of ZFs bound to DNA​9​. The 
mechanism of ZFNs (​Figure 1​), for maximum efficiency, requires two sets of ZFs with one 
complementary to one side of the dsDNA linked to their respective ​FokI ​cleavage domains. The 
two cleavage domains then dimerize to create a single cleavage domain that then proceeds to 
create the DSB.  
 
6​Figure 1.​ Zinc Finger Nuclease mechanism of binding and cleavage. F1, F2, F3 are binding 
domains (ZFs). The ​FokI​ restriction enzyme molecules (cleavage domain; yellow boxes) dimerize and 
cleave at points indicated with the black arrows. 
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There are a multitude of drawbacks, with this technology all stemming from the specificity that 
results in issues such as cytotoxicity​10​ of ZFNs due to off-site targeting, a common issue with 
earlier genome editing tools. TALENs, the second tool to develop within the genome-editing 
field is similar to the ZFNs in that it utilizes the ​FokI ​nuclease as the cleavage domain for DSBs, 
but also has a separate binding domain. Transcription activator-like effectors (TALEs) are 
proteins discovered in Xanthomonas bacteria that serve to infect host plant cells and change gene 
transcription within the host​11​. The TALEs contained conserved repeat sequences (​Figure 2​) that 
researchers were able to specify towards target-binding sites in dsDNA and with the ​FokI 
nuclease linked to the TALEs binding domain create DSBs in DNA.  
 
7​Figure 2.​ TALENs diagram depicts the TALE repeat domains that bind to dsDNA and the ​FokI 
nuclease domain that creates the DSBs in dsDNA. 
 
Another commonality that TALENs, unfortunately, has with ZFNs is the high probability for 
off-targeting DSBs and this is due to TALENs genome-wide ability to bind to dsDNA. TALENs 
and ZFNs are extremely efficient in causing DSBs, but the main issue is how to control what 
type of mutagenesis occurs after the cutting happens.  
Mutagenesis is the main purpose for every genome editing tool, but one of the main 
drawbacks for this is the lack of control researchers have over the type of mutation that occurs. 
Mutations occur within DNA after the cleavage of the dsDNA strands as the cell tries to repair 
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the broken strands which can go down two different pathways of repair: non-homologous 
end-joining repair (NHEJ) or homology-directed repair (HDR) (​Figure 3​).  
 
12​Figure 3. ​ Non-homologous end-joining repair (NHEJ) and homology-directed repair (HDR) 
effect on the target genome after the CRISPR-Cas9 system created a DSB in the dsDNA.  
 
NHEJ repair is more prone to indel mutations where sequences within the target DNA could be 
inserted, deleted, or both. Through insertion and deletions of the target genome, frameshifts can 
occur where the entire reading frame is shifted breaking up codons. This results in the 
deactivation or overactivation of genes and subsequently shutting off or overproducing protein 
production which could lead to a variety of problems such as cancer, cell death, et cetera NHEJ 
is thought to be during the G1 phase of a cell​15​. HDR repair utilizes a homologous DNA 
sequence to insert into the target genome allowing for a precise edit to the target genome of 
choice. The homologous DNA (similar or identical DNA) donor template could be 
single-stranded oligonucleotides (ssODNs) or dsDNA, and with genome editing tools such as 
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ZFNs, TALENs, or CRISPR-Cas9 the template donor would be dsDNA on the account of the 
DSB in the target genome​13​. The determination of which DNA repair pathway is largely based 
around DSB resection, which is where a DSB is altered into a 3’ single-stranded DNA 
overhang​13,14​. A long 3’ single-stranded DNA overhang is a requirement for HDR, and without it, 
the DNA repair pathway will undergo NHEJ​14​. Unlike NHEJ, HDR is believed to be done during 
the S and G2 phase​15​. The variety in which a cell can repair the DSBs after genome editing tools 
are used is an ever-expansive area of research as being able to predict or even control what repair 
pathway is used gives this technology the ability to be used to a far greater capacity.  
The importance of genome editing comes from its inherent benefits in the control over 
the genetic makeup as this has a vast array of uses due to the imperative role dsDNA has in all 
living organisms. The medical field could use genome editing, and with even more success now 
due to the CRISPR-Cas9 system, to cure genetic diseases, and possibly provide some insight into 
diseases such as Alzheimer's​16​. Within the food industry​17​, genome editing has already improved 
productivity and quality of crops produced, and with CRISPR-Cas9 there are numerous problems 
that can be tackled more efficiently (​Figure 4​).  
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17​Figure 4​. CRISPR-Cas9 system’s potential areas of usage within the Food/Crop production 
industry. 
 
One last example of the applicability and possibility for this CRISPR-Cas system is the 
usage it has in the fight against the ongoing COVID-19 pandemic. Research labs, such as Omar 
O. Abudayyeh’s​18​, have been able to engineer a CRISPR-Cas13a system to target RNA and 
effectively bind and knockdown the RNA transcripts as a result. This system has a high 
specificity and has the ability of RNA knockdown in mammalian cells which could prove 
beneficial in fighting COVID-19’s viral RNA. In the New York Genome Center, researchers 
such as Neville Sanjana​19​ are also utilizing the CRISPR-Cas13 system to be able to target RNA 
rather than DNA. The research group has also been able to identify optimal guide RNAs to be 
able to detect COVID-19 viral RNA in the future but could also open doors to therapeutic 
applications for the virus. The possibilities are endless with genome editing, and with the 
CRISPR-Cas9 system, a majority of these possibilities could become reality.  
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II.) Development of the CRISPR-Cas9 System as a Genome Editing Tool 
Clustered Regularly Interspaced Palindromic Repeats (CRISPR) were first discovered in 
Escherichia coli ​(​E. Coli​)​ ​and ​Salmonella Typhimurium ​ ​in 1987 by Ishino Y. et al​20,21​ while 
sequencing a gene within the E. Coli genome responsible for isozyme conversion of alkaline 
phosphatase. Ishino’s research group discovered that towards the 3’ end of the ​iap​ gene five 19 
nucleotide sequences that were exactly alike separated by 32 nucleotides. These sequences were 
named REP sequences by Ishino’s research group. The only differences found between the five 
sequences were two nucleotides that were not homologous with the REP sequences (​Figure 5​).  
21​Figure 5. ​Ishino’s research group’s comparison of the five REP sequences with the two 
nucleotide differences being in between the underlined sequence. 
 
The REP sequences were hypothesized to be within the prokaryote’s genome for mRNA 
stabilization by Ishino’s research group. The two nucleotides that were different between the five 
sequences, unbeknownst to the research group at the time, were the PAM sequences that are 
cleavage sites for the CRISPR-Cas system. The discovery of these REP sequences sparked the 
beginning of research into these mysterious sequences within the prokaryotic' genomes and the 
purposes they have.  
Seven years later, Mojica et. al discovered the same REP sequences within ​Haloferax 
mediterranei​ and ​Haloferax volcanii Archaeal genomes​20,22​. This discovery is important due to 
the fact that it reinforces the theory that REP sequences are characteristic of prokaryotes, and this 
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defense mechanism is indiscriminate across differing genomes of prokaryotes. This implies the 
versatility and applicability of this genome editing technology across different organisms and 
species. The purpose of these REP sequences was lost on the researchers up until the early 2000s 
when multiple research groups​20,23,24,25​ published findings on the functionality of the REP 
sequences within prokaryotic and archaeal genomes. The research by Mojica​23​, Pourcel​24​, and 
Bolotin​25​ all corroborated a mechanism that these REP sequences are interspaced with DNA in 
between from an extrachromosomal origin as a collected memory of viral attacks by 
bacteriophages (viruses that infect bacteria). The term REP sequence was revised to Clustered 
Regularly Interspaced Palindromic Repeats (CRISPR) upon these research findings. A major 
discovery by Bolotin’s research group was the discovery of the Cas9 gene that encodes for a 
large protein that they predicted to have nuclease activity. Yet another major finding of their 
research group was that the spacer regions all have a common sequence at 3’ ends of the 
sequence. This was the protospacer adjacent motif (PAM) sequence that is required for 
recognition and subsequent cleavage by the Cas9 protein. 
 In the research by Mojica​23​ and Pourcel​24​, there were hypotheses of the ​cas​ genes 
discovered upstream of the CRISPR sequences and spacers were somehow involved in the 
process of uptake of foreign DNA in this newfound prokaryotic immune system. In Pourcel’s 
research findings, the ​S. thermophilus​ strains that had the most spacers within their CRISPR 
locus had lower phage sensitivity than strains that did not. 
 It was not until 2007​20​ that some of the mechanism (​20​Figure 6​) of the CRISPR-Cas 
system was experimentally proven by Barrangou et. al​26​.  
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20​Figure 6. ​CRISPR-Cas System mechanism for prokaryotic organisms’ immune system. 
 
The research group injected a bacteriophage sequence into one of the spacer regions in between 
CRISPR sequences and found that they had made the ​S. thermophilus​ resistant to the 
bacteriophage from where the injected sequence originated. However, the research group did not 
understand the intermediary mechanism involving CRISPR RNA (crRNA) (Figure 6). This 
intermediary mechanism was elucidated in 2008 by Brouns’ research group​27,28​ while studying 
the antiviral defense of​ E. Coli. ​The research group had concluded that five Cas proteins are 
responsible for the creation of the pre-crRNAs and maturation of the crRNAs to be used as a 
guide to viral RNA within the bacteria. The five Cas proteins form a protein complex that 
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recognizes a stem-loop formed by the CRISPR sequences (​28​Figure​ ​7​) with the cleavage site for 
the pre-crRNA region being a few nucleotides downstream of the stem-loop.  
 
28​Figure 7.​ Diagram of CRISPR sequences forming stem-loops used for recognition by Cas 
protein complex to cleave pre-crRNA for antiviral defense.  
 
The spacer region in Figure 7 is the pre-crRNA sequence that will mature into small crRNA that 
will serve as a guide to binding to viral DNA produced from the reverse transcription of viral 
RNA and be cleaved by the Cas-sgRNA complex.  
The next major step in the development of the CRISPR-Cas system as a genome-editing 
tool was the discovery of the trans-activating CRISPR RNA (tracrRNA) in ​Streptococcus 
pyogenes ​by Deltcheva et. al’s research group​29​ in 2011. The purpose of tracrRNA concluded by 
the research group was to help facilitate the maturation process of pre-crRNA to small crRNA 
alongside RNAse III, and a Cas protein, Csn1. tracrRNA has 24 nucleotides of complementarity 
to the repeat regions found within the pre-crRNA transcripts​29​ and therefore binds to the 
pre-crRNA creating an RNA duplex. This RNA duplex is recognized by the RNAse III, and is 
subsequently cleaved, but only in the presence of the Csn1 Cas protein yielding the individual 
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repeat-spacer-repeat units. These units are then processed again, but the mechanism (​29​Figure​ ​8​) 
has yet to be understood as reported by Deltcheva’s research group. 
 
 
29​Figure 8.​ tracrRNA creates an RNA duplex with pre-crRNA for processing by RNAse 
III and Csn1 Cas protein to yield mature crRNA for antiviral defense. 
 
In the next year, Siksnys’​30​ and Jinek’s (collaborating with Charpentier and Jennifer 
Doudna’s lab)​31​ research groups both published separate findings on the CRISPR-Cas9 system 
effectively causing DSBs within different genomes. In Siksnys’ research, they further proved the 
importance of two major components of the genome editing system: the PAM sequence and the 
crRNA. The research group conducted cleavage assays with and without a PAM sequence and 
concluded that without a PAM sequence that cleavage would not occur efficiently. They also 
experimented with the crRNA used to bind to the genome target and showed that if they alter the 
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crRNA sequence they can effectively reprogram Cas9 to target any genome target they desired. 
A more minor finding within this paper is that they discovered the optimal size of the crRNA for 
binding to a dsDNA target is 20 nucleotides. In Jinek’s research, the targeting system for the 
CRISPR-Cas9 genome editing tool was made more efficient by the discovery that the crRNA 
and tracrRNA could be bound together into one single guide RNA (sgRNA). This allows for a 
more refined and efficient targeting process for creating DSBs with the Cas9 protein (​31​Figure 9). 
Before this finding, the Cas9 protein relied on a two RNA system (crRNA and tracrRNA) to 
target the desired genome, but now the two RNA strands can be joined synthetically by fusing 
the 3’ end of the crRNA to the 5’ end of the tracrRNA.  
 
31​Figure 9. ​Differences in the CRISPR-Cas9 system mechanism based on the 
crRNA:tracrRNA duplex (two RNA system) and the single chimeric RNA (sgRNA). 
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The sgRNA discovery allows for enhanced specificity and a reduction of offsite targeting by the 
Cas9 protein as the Cas9 is only able to cut where this sgRNA and PAM sequence is present. 
There has been an abundance of findings that have assisted in the progression of the 
CRISPR-Cas9 system as an effective genome editing tool. The ones listed are but a small sample 
but have been proven to be the most pioneering and enlightening in the development of this 
technology. Even though there has been exponential progress on the CRISPR-Cas9 system​32 
there is still so much that is unknown about it such as: how to control the amount of DSBs after 
introducing the sgRNA-Cas9 complex into an organism, how to effectively eliminate offsite 
target mutations caused by minor inaccuracies in the Cas9 identification of a cutting site, and 














III.) CRISPR-Cas9 System Components 
● Streptococcus Pyogenes (Spy.)​ Cas9​ ​Protein/Enzyme 
The Cas9 protein (1, 368 amino acids​35​) was discovered in the gram-positive bacteria, 
Streptococcus pyogenes​, and has become the most widely used Cas protein (hereafter referred to 
as SpyCas9) in genome editing due to its ability to target any dsDNA target if complexed with 
sgRNA. The SpyCas9 protein is a type II CRISPR-Cas system​33​. There are six types of 
CRISPR-Cas systems (I-VI) in total, but the main ones used for genome editing are types I-III​34​. 
The CRISPR-associated (​cas​) genes encode for a variety of different Cas proteins with each one 
following into one of the six types of CRISPR-Cas systems. The CRISPR-Cas system is 
classified into one of the six types based on accessory RNA guides used and the number of Cas 
proteins used to facilitate recognition and cleavage of dsDNA. For example, Type I and III 
systems of CRISPR-Cas utilize many Cas proteins (5-7 proteins used) coupled with crRNAs to 
be able to recognize and cleave the target dsDNA. The type II CRISPR-Cas system utilizes only 
one Cas protein complexed to an RNA duplex (crRNA and tracrRNA) or sgRNA (crRNA and 
tracrRNA synthetically fused together) to bind and cleave dsDNA targets. Another feature of 
type II CRISPR-Cas systems is the requirement of a PAM sequence for recognition of the 
desired cleavage site (this feature is shared with type I systems as well)​33​. 
While SpyCas9 is structurally a protein, it is, however, functionally an enzyme (labeled 
as such from here on out). The SpyCas9 enzyme contains two main lobes: the REC (recognition) 
and the NUC (nuclease) lobes (​35​Figure 10​).  
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35​Figure 10. ​A: Crystal structures of the SpyCas9 enzyme with the NUC lobe and REC lobe 
labeled. B: RuvC endonuclease domain. C: HNH endonuclease domain. 
 
These two lobes are connected through an arginine-rich bridge that contorts into a helical shape 
as well as a disordered linker (residues 712-717)​35​. The REC lobe is made up of three 
alpha-helical domains known as Hel-I, Hel-II, and Hel-III. These three domains do not share 
similarities in structure with any other known proteins​35​. Within the three domains, there are 
PAM interacting sites that are responsible for recognizing target sites based on whether a PAM is 
present or not. These interacting sites are kept inactive due to the apo-conformation of the 
SpyCas9 protein, but once the SpyCas9 protein is complexed with sgRNA these sites become 
accessible for recognizing PAM sites​35​. 
Within the NUC lobe of the SpyCas9, there are two endonuclease domains: the HNH and 
RuvC domains (refer to ​35​Figure 10​). These domains are solely responsible for the DSBs of the 
target genome through different mechanisms. The HNH nuclease domain is known to cleave the 
target strand of the target dsDNA. The HNH domain within the SpyCas9 enzyme is similar to 
other HNH endonucleases in that it follows the same fold that other HNH endonucleases within 
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the family have: the ββα-metal fold. The proposed mechanism for cleaving the target DNA 
strand by the HNH domain is through a one-metal-ion-mechanism but could also be done 
through a two-metal-ion mechanism​35​. Upon the SpyCas9-sgRNA complex binding to the 
dsDNA target, the dsDNA begins to unwind, allowing for the cleavage domains to bind and 
subsequent mechanisms to cause DSBs. The HNH cleavage happens instantaneously after the 
unwinding of the dsDNA which then leads to the RuvC domain to cleave the non-target strand. 
The RNAse H fold characterizes the RuvC domain. The proposed mechanism for this domain is 
a two-metal-ion mechanism with the metal primarily being magnesium that is used to create 
DSBs in the non-target strand of dsDNA. The cleavage by the RuvC domain is only possible if 
the HNH cleavage has occurred as the binding of the HNH domain creates a conformational 
change that activates the RuvC domain​37​. These two domains are essential to the overall genome 
editing technology to inflict changes in dsDNA targets, but definitive mechanisms are yet to be 
elucidated through experimental data​34,35,36​.  
● Single-Guide RNA (sgRNA) 
Type-II CRISPR-Cas systems, such as SpyCas9, require the presence of a 
crRNA:tracrRNA duplex in order to effectively target and cleave dsDNA substrates. The crRNA 
and tracrRNA duplex have since been consolidated through covalently linking the 3’ end of the 
crRNA to the 5’ end of the tracrRNA into a single-guide RNA (sgRNA). The sgRNA guide is 
essential to the CRISPR-Cas9 system’s specificity, and precision as cleavages primarily occur 
where the sgRNA guide is bound, and a PAM sequence is present. The SpyCas9 enzyme is 
guided to potential cut sites by binding to the target DNA strand (strand lacking PAM sequence) 
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creating an R-loop formation that allows for the REC lobe of the SpyCas9 enzyme to detect a 
PAM sequence on the target strand (​37​Figure 11​).  
 
37​Figure 11.​ R-loop formation created by the sgRNA guide binding to the complementary 
strand (strand without PAM sequence). 
 
The R-loop formation allows for subsequent cleavage by the HNH and RuvC endonuclease 
domains by the NUC lobes of SpyCas9​38​. This formation also allows for the REC lobe to detect 
for a PAM sequence on the non-target strand before the NUC lobes create the DSBs in the target 
genome. 
Effective sgRNA guides have crRNA sequences 18-24 nucleotides long that are 
complementary to the target strand of DNA​39​.  
● dsDNA Target  
The CRISPR-Cas9 system will bind and cleave to any dsDNA target as long as two 
components are found within the dsDNA target. The dsDNA target must contain both: an 18-24 
sequence complementary to that of the sgRNA guide and a PAM sequence that is recognized by 
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the Cas9 enzyme. Without one or both of these components, the dsDNA target experiences little 
to no cleavage as a result of a lack of recognition by the Cas9-sgRNA complex​39​. The PAM 
sequence 5’-NGG-3’, where “N” is any nucleotide and “G” is guanine, is recognized by the 
SpyCas9 enzyme as a cleavage site and subsequently leads to a DSB three base pairs upstream of 
the PAM sequence in the genome target by the HNH and RuvC domains​38,39​. There is no 
definitive size requirement for the dsDNA substrate excluding the prerequisite 18-24 sequence 

















IV.) Drug Targeting of the CRISPR-Cas9 System 
One of the main areas of research in the CRISPR-Cas9 system as a genome-editing tool 
is how to effectively slow and/or stop cleavage once this system has been introduced into an 
organism. SpyCas9 is an enzyme, and once complexed to the sgRNA, it will continue to cleave 
wherever the guide is complementary which can lead to excess cleavage. The SpyCas9’s ability 
to cleave dsDNA is entirely dependent upon the sgRNA guide being complementary to the 
non-target strand and a PAM sequence is present in the dsDNA target. There could be a possible 
way to affect the cutting efficiency of the CRISPR-Cas9 system by targeting the sgRNA guide. 
While this possibility could be helpful in reducing off-site targeting mutation, and the subsequent 
consequences, affecting the cutting efficiency of the CRISPR-Cas9 system could be useful in the 
fight against bacteria and bacterial infections as this system originated as a bacterial defense 
mechanism against viruses​20​. By reducing the cutting efficiency of the CRISPR system in 
bacteria, viruses, specifically, bacteriophages could be utilized to fight bacterial infections as 
they would not be targeted by the defense mechanism any longer.  
Within Prof. Swapan Jain’s RNA research lab at Bard College, the research is geared 
towards known RNA binding drugs and experimental metal-based complexes​40,41​ with RNA 
affinity affecting RNA processes such as mRNA expression. A variety of metal complexes 
synthesized in collaboration with Prof. Craig Anderson’s Organometallics lab were tested 
alongside known RNA binding drugs such as Cisplatin. A trinuclear Ru(III)/Pt(II) metal complex 
proved to have a higher RNA binding affinity than that of Cisplatin​41​. Even though Cisplatin, a 
chemotherapy medication used for fighting cancer, was experimentally lower in RNA binding 
affinity than that of the trinuclear metal complex it could still be used as a potential counteragent 
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to sgRNA. A proposed counteragent is an RNA binding drug or metal complex that interferes 
with the complexing of the SpyCas9 enzyme and/or dsDNA target. This is believed to be a 
possible mechanism of reducing the cleavage efficiency of the CRISPR-Cas9 system. In 
addition, the cleavage efficiency of the CRISPR-Cas9 system is highly correlated to the target 
strand and sgRNA folding stability​42​. The folding stability could be affected by an RNA binding 
drug such as Cisplatin or even a metal complex based molecule that has been produced in Prof. 
Swapan’s lab.  
In Prof. Swapan Jain’s lab, a dinuclear metal complex’s​40​ ability to inhibit RNA mobility 
was proposed to have been done so by creating conformational changes in the RNA on the 
account of it being bound to multiple metal centers through intramolecular cross-linking. This 
could be useful in affecting cutting efficiency by conformationally changing the sgRNA guide 
making it inaccessible to complex with the SpyCas9 enzyme. Even if the same conformational 
changes do not occur as were proposed in Prof. Swapan’s research, the large metal complex 
could sterically hinder the SpyCas9 from engaging the sgRNA guide that is necessary in order to 
complex with it.  
The main purpose of this thesis was to create an effective in-vitro cleavage assay for the 
CRISPR-Cas9 system that would be used for further studies. The focus for the studies being on 
the effects of these RNA binding drugs and metal complexes on the sgRNA guide’s 
functionality, and how affecting the functionality affects the overall ability of the CRISPR-Cas9 







I.) Determining dsDNA Substrate from pUC19 Plasmid 
The dsDNA substrate was yielded from pUC19 (2686 bp) DNA Plasmid purchased from 
ThermoFisher Scientific. Three possible dsDNA substrates with one PAM sequence ranging 
from 110-160bp in length had DNA primers (stored in Nuclease-Free water at -20℃) ordered 
from Integrated DNA Technologies (IDT) for subsequent PCR (Table 1). Melting temperatures 
were calculated for each Primer sequence listed on the IDT website with the following 







































Forward: 55.1 ℃  

















Forward: 66.6 ℃  

















Forward: 55.2 ℃  
Reverse: 56.9 ℃  
Table 1.​ Three potential dsDNA substrates located within the pUC19 DNA Plasmid for In-vitro cleavage 
assays with the CRISPR-Cas9 system. PAM sequences are highlighted in red. Melting temperatures were 
calculated for each Primer sequence listed on the IDT website with the following parameters: 10𝜇M 
Oligo, 50mM Na​+​, 2mM Mg​++​, 0mM dNTPs. 
 
II.) Creating Working Stocks of DNA Primers for Polymerase Chain Reaction 
Working stocks of 10𝜇M (in Nuclease-Free water) were created from the original DNA 
Primer Stocks using Beer’s Law (​Figure 12​). Extinction coefficients (𝜺) were given by IDT on 
information sheets for each individual DNA primer. Nanodrop UV-Vis was used to obtain the 
A​260​ value for each DNA primer. DNA primers’ stock concentration (Figure 12) was used to 
calculate the dilution needed to obtain a 10𝜇M working stock. Original DNA primer stocks and 





Figure 12.​ Example calculations to obtain the concentration of DNA Primer stocks. Calculation 
of dilution needed to obtain 10𝜇M working stocks for Polymerase Chain reactions to yield dsDNA 
















III.) Polymerase Chain Reaction to Yield dsDNA Substrates 
PCR protocol was adapted from New England Biolabs​43​. The PCR was run at a volume 
of 50uL with alterations made in the amounts of Template DNA (0.5𝜇g/𝜇L), Forward/Reverse 
Primers (10𝜇M), and dNTPs (10mM) as well the addition of MgCl​2​ (2mM) (​Table 2​).  
 
Reagent (Concentration): Amount Added: 
10X PCR Buffer 5𝜇L 
dNTPs Mix (10mM) 2𝜇L 
Forward/Reverse Primers (10𝜇M) 2.5𝜇L (each) 
pUC19 Plasmid (0.5ug/𝜇L) 1𝜇L 
Taq ​DNA Polymerase (5U/𝜇L) 1𝜇L 
MgCl​2 ​(2mM) 4𝜇L 
Nuclease-free water 32𝜇L 
Reaction Total: 50𝜇L 
Table 2.​ All of the components included in the PCR reaction to create DNA substrates listed in Table 1.  
 
The PCR reaction, microcentrifuge tubes were placed into a BioRad MyCycler thermal cycler to 
facilitate the temperatures needed for the polymerase chain reaction to occur. The BioRad 
MyCycler thermal cycler went through four different stages throughout the reaction: 
denaturation, initial extension, final extension, and hold (​Table 3​). The thermal cycler protocol 
used was adapted from Prof. Swapan’s Chemistry 350 ​Physical and Analytical Techniques 
course. The entire thermal cycler protocol would run approximately two hours in total. The PCR, 
microcentrifuge tubes sat in the thermal cycler at a constant 4℃ until collected for purification or 
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stored at -20℃. 2𝜇L of unpurified PCR product was used for Nanodrop UV-Vis to acquire  A​260 
and A​260/280​ values. 
 
Stage: Time:  Temperature (℃): 
Denaturation 120 sec 95℃ 
Initial Extension 
(40 Cycles) 
15 sec (Melting) 
30 sec (Hybridization) 




Final Extension 10 mins 68℃ 
Hold Infinite  4℃ 
Table 3.​ Polymerase chain reaction protocol for the Thermal Cycler stages, the longevity of stage, and 
temperature of each stage.  
 
IV.) Purification of dsDNA Substrate 
Products from PCR reactions were purified using a Qiagen PCR Purification kit (Cat. No. 
28106) that utilizes silica-membrane-based purification to extract dsDNA. The Qiagen kit allows 
for dsDNA PCR products ranging from 100bp to 10kb to be purified and isolated. 5𝜇L of the 
unpurified PCR product was set aside for gel analysis. The PCR products were transferred to a 
mini-spin column attached to a 2ml collection tube for supernatant removal. 225𝜇L of PB Buffer 
was added to the mini-spin column and then placed into a centrifuge to spin at 13,000rpm for 
thirty seconds. The supernatant, in the collection tube, was emptied and then reattached to the 
spin column. 675𝜇L of PE buffer was added to the spin column and then centrifuged at 
13,000rpm for sixty seconds. The collection tube was emptied again and then reattached to the 
mini-spin column to be centrifuged at 13,000rpm for sixty seconds once more. The collection 
tube was removed and the mini-spin column was attached to a 1.5ml microcentrifuge tube. 50𝜇L 
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of pre-heated (50°C) Elution Buffer was added directly to the silica membrane within the 
mini-spin column and allowed to sit at room temperature for 1 minute. The mini-spin column 
attached to the microcentrifuge tube was centrifuged at 13,000rpm for 1 minute. 2𝜇L of the 
purified PCR product was then analyzed using Nanodrop UV-Vis to acquire the A​260​ and A​260/280 
values. The purified PCR product was stored at -20°C until further use.  
V.) Gel Electrophoresis of Purified dsDNA Substrates 
A 2.5% agarose gel was utilized to analyze the size of the pure and impure dsDNA 
substrates. 1.5 grams of Agarose was added into 60ml of 1X TBE buffer and then heated within 
a microwave for approximately 50 seconds. 6𝜇L of the Sybr-Green 10,000x (ThermoFisher Cat. 
#S-7567) staining agent was added to the mixture once it reached a temperature of 65℃. The gel 
mixture was poured into a small gel cast with an eight well comb and allowed to solidify. 6𝜇L of 
the purified PCR products were mixed with 2𝜇L of 6X purple gel loading dye and loaded into 
their respective wells. 5𝜇L of unpurified PCR products were mixed with 1𝜇L of 6X purple gel 
loading dye and loaded into their respective wells. 4𝜇L of low molecular weight DNA ladder 
(NEB, cat. #N3233L) was used for size analysis. A BioRad Mini-Sub Cell GT Horizontal 
Electrophoresis System (cat. #1704406) and a Biorad PowerPac Basic Electrophoresis Power 
Supply (cat. #1645070) were used to run the gel protocol. Approximately 300mL 1X TBE buffer 
was added to the Mini-Sub Cell GT system to submerge the gel. The power supply ran at a 
constant 150V for approximately 1 hour. The gel was placed onto a UV Sample Tray (cat. 
#1708271) and imaged using a BioRad Gel Doc​™​ EZ System (cat. #1708270) and BioRad 
Image Lab Software. 
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VI.) sgRNA Guide for In-Vitro Cleavage Assay 
The sgRNA guide was purchased from Synthego. The sgRNA guide was created using 
the Synthetic sgRNA CRISPR Kit tool from Synthego. A 20nt crRNA sequence was given to 
Synthego, which was then attached to an​ ​80nt SpCas9 scaffold to create the single guide RNA. A 
100uM stock of sgRNA Guide (10 nmoles) was created by adding 100uL of 1X TE buffer. The 
sgRNA stock was stored in a -20℃ freezer until further utilized. 
 
VII.) In-Vitro Cleavage Assay Using the SpyCas9 System 
The protocol for the in-vitro cleavage assay was given for use by Raed Ibraheim from the 
Sontheimer Lab at the University of Massachusetts Medical School and adapted for the use of 
the SpyCas9 protein. The NEB buffer 3.1 and SpyCas9 protein (20𝜇M stock; cat. #M0386T) was 
purchased from New England Biolabs. 3𝜇M working stocks of SpyCas9 protein and sgRNA 
guide were made. The purified dsDNA stock of AF1 was used to make a 10nM working stock. 
Proteinase K was purchased from ThermoFisher Scientific (cat. # EO0491). All of the reagents 









Reagent (Concentration): Amount Added (𝜇L): 
NEB Buffer 3.1 2 
sgRNA (3𝜇M) 2 
SpyCas9 Protein (3𝜇M) 4 
AF1 dsDNA Substrate (10nM) 4 
Nuclease-Free Water 13 
Proteinase K (after reaction) 1 
Total Reaction Amount: 26 
Table 4.​ List of reagents used in the SpyCas9 in-vitro cleavage assay. Proteinase K was added to the 
reaction after the incubation time to remove the SpyCas9 protein before gel analysis.  
 
13𝜇L of nuclease-free water was added to a microcentrifuge tube. 2𝜇l of NEB buffer 3.1 and 
sgRNA (3𝜇M) were both added to the microcentrifuge tube. 4𝜇L of SpyCas9 (3𝜇M) was added 
to the microcentrifuge tube and then allowed to incubate at room temperature for 15 minutes. 
4𝜇L of 10 nM purified AF1 dsDNA substrate was added to the microcentrifuge tube and then 
placed onto a heat block for incubation at 37℃ for 1 hour. The microcentrifuge tube was then 
removed from the heat block and 1𝜇L of Proteinase K was added. The microcentrifuge tube was 
placed back onto a 50℃ heat block for 10 minutes for protein degradation. A 2.5% agarose gel 
was used for size analysis (for more information on size analysis and imaging procedures refer to 










The development of this thesis occurred in chronological order of developing a dsDNA 
substrate target then designing a sgRNA guide in order to target the desired dsDNA substrate, 
and finally compiling the three main components (see section III of introduction) into an in-vitro 
cleavage assay. The results are displayed in the same chronological order as to display the 
methodology that went into testing the overall hypothesis for this thesis. 
I.) dsDNA Substrate from pUC19 Plasmid 
The PCR reaction and subsequent purification were successful for two of the three 
designed dsDNA substrates (​Figure 13​). Samples of the unpure PCR product were run alongside 
the purified samples of PCR products on a 2.5% agarose gel. AF1 (156bp) and AF2 (113bp) 
were both confirmed through size analysis using a 100bp DNA ladder.  
 
Figure 13.​ A: Gel electrophoresis of purified and unpurified PCR products on a 2.5% agarose 
gel. A 100Bp DNA ladder was used for size comparison. B: Nanodrop UV-Vis absorbance values for 
A​260​, A​260​/A​280​, and A​260​/A​230​ of the AF1, AF2, and AF3 dsDNA substrates.  
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AF3 was not confirmed through gel analysis and was not selected as the target dsDNA substrate 
for the sgRNA design and synthesis. AF1 was selected as the target dsDNA substrate for the 
in-vitro cleavage assays based on it having the highest A​260​ value (indicating a higher amount of 
DNA), and qualitatively, the most intense and distinct band on the gel analysis out of the other 
proposed dsDNA substrates.  The A​260​/A​230​ value of AF1 was noted as it was quite low compared 
to the recommended value range​44​ of 2.0-2.2 indicating the presence of contaminants as can be 
qualitatively seen at the top of the gel. This could be leftover pUC19 plasmid not removed 
through the purification process. The amount of AF1 dsDNA substrate was calculated using the 








Figure 14.​ Calculation of the amount of AF1 dsDNA substrate yielded from the PCR purification 
reaction in nanograms. Calculation and dilution of AF1 dsDNA stock to a 10nM working stock for 
in-vitro cleavage assay. 
 
 
The concentration of AF1 stock was calculated in nanomolar (nM) using a conversion equation 
to convert dsDNA stocks in ng/𝜇L to nanomolar​45​. A dilution was then calculated to create a 
10nM working stock for the CRISPR-SpyCas9 in-vitro cleavage assays.  
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II.) Design of sgRNA guide for AF1 dsDNA Substrate 
The sgRNA guide was designed based on the results of the PCR reaction and purification 
of the three possible dsDNA substrates. The AF1 dsDNA substrate was chosen to be used as the 
DNA target for the in-vitro cleavage assays (refer to ​Section I​ of results/discussion). Only one 
sgRNA guide was created in efforts to conserve the budget for other equipment/ materials. A 20 
nucleotide complementary crRNA sequence was created for the target strand (strand lacking 
PAM sequence; 3’ strand of DNA) of the AF1 dsDNA substrate. The custom crRNA sequence 
was sent to Synthego where the desired crRNA sequence was fused to a tracrRNA designed by 
Synthego (​Figure 15​).  
 
Figure 15.​ Single-guide RNA 
design. crRNA sequence 
complementary to AF1 
dsDNA substrate with 
scaffold RNA sequence by 











The tracrRNA designed by Synthego was 80 nucleotides long with the sequence being unknown 
as it was not divulged. This tracrRNA scaffold is designed specifically for high-efficiency 
recognition by the SpyCas9 enzyme (refer to ​Figure 15​). In total, the sgRNA guide was 100 
nucleotides long with 20 nucleotides being complementary to the target dsDNA substrate and 80 
nucleotides were designed for the recognition by the SpyCas9 protein. 
The sgRNA stock (approximately 100 𝜇M) was used to create a 3𝜇M working stock for 
the CRISPR-SpyCas9 in-vitro cleavage assays (​Figure 16​).  The 3𝜇M working stock was stored 
at -20℃ until further utilized.  
 






III.) CRISPR-Spy Cas9 In-Vitro Cleavage Assays 
There were no successful in-vitro cleavage assays that displayed cleavage activity by the 
SpyCas9 enzyme. A total of seven in-vitro cleavage assays were conducted. Two of the assays 
were conducted according to the protocol given by Raed Ibraheim, a Ph.D. candidate from the 
University of Massachusetts, but the last five assays had varying incubation times (at 37℃ step) 
and differing concentrations of either SpyCas9 enzyme or sgRNA guide.  
The first in-vitro cleavage assay (​Figure 17​) was not successful as there is no band 
adjacent to the 75 base pair band from the low molecular weight DNA ladder indicating that no 
DNA is present in this size. A single band was predicted to be present around this size indicator 
as the cleavage site is near the middle of the AF1 dsDNA substrate creating two strands 
approximately 78 base pairs long, therefore, the two bands would overlap creating a single band 
during gel analysis.  
Figure 17.​ 2.5% Gel analysis of unsuccessful CRISPR-SpyCas9 In-Vitro Cleavage Assay 
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The next six in-vitro cleavage assays were all run on the same gel alongside the uncut 
AF1 dsDNA and a low molecular weight DNA (​Figure 18​). One of the six assays was run 
according to the protocol from the first in-vitro cleavage assay as a control against the 
experimental variables of longer incubation times or varying concentrations of SpyCas9 enzyme 
or sgRNA.  Three conditions had a 4-hour incubation at 37℃ with one having normal 
concentrations and the other two have 6𝜇M sgRNA or 20𝜇M SpyCas9 enzyme. The last two 







Figure 18.​ 2.5% gel analysis of varying conditions placed on the CRISPR-SpyCas9 in-vitro 
cleavage assay in order to troubleshoot the original protocol.  
 
The reasoning for the varying conditions in the original protocol for the in-vitro cleavage assay 
was to troubleshoot and determine if there was a single step causing a failure in ascertaining 
positive results of cleavage occurring. The lack of any bands appearing within a gel could be due 
to a number of reasons ranging for mishandling of the samples while loading into the gel, 
insufficient amounts of samples loaded into each well, the samples leaking out of the wells, or 
the gel being run for too long allowing for the samples to run off of the gel into the buffer 
surrounding the gel. However, none of these issues except for the lower amount of sample for the 
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uncut condition were present while preparing and running the gel in figure 18. A lower amount 
of AF1 dsDNA substrate uncut was loaded into the gel as most of the remaining stock had been 
utilized in the varying conditions of the in-vitro assays which could explain the lack of a band 
around the 150 bp size marker.  
After these seven attempts, it was hypothesized that the reason that the cleavage of the 
AF1 dsDNA substrate could be due to the inactivity of the purified SpyCas9 enzyme which was 
bought approximately 8 months prior to the date of these in-vitro cleavage assays. There were 
also several power outages that occurred during this time span that could have affected the 
overall activity of the SpyCas9 enzyme stock. A new SpyCas9 enzyme stock (20𝜇M) was 
ordered from the previous supplier, but before the enzyme was able to be used in the same 
procedure as the assays in figure 18, the Reem-Kayden Center for Science and Computation was 
closed down indefinitely due to the escalation of the COVID-19 virus. The closure due to the 
impending COVID-19 pandemic effectively ended further experiments from being completed. 
The next section will consist of hypothetical results that were to be expected from further 
experimentation. 
IV.) Hypothetical Results  
Before moving onto testing the hypothesis of small RNA binding drug molecules 
affecting cleavage efficiency of the CRISPR-SpyCas9 system, a successful in-vitro cleavage 
assay would be required. A successful in-vitro cleavage assay would ensure each component 
(sgRNA, SpyCas9, and dsDNA substrate) were able to complex and the enzyme was able to 
recognize the custom sgRNA guide and dsDNA substrate and function accordingly by causing 




Figure 19.​ Hypothetical gel electrophoresis results for a successful CRISPR-SpyCas9 in-vitro 
cleavage assay. A low molecular weight DNA ladder was used for size comparison. 
 
The subsequent high-resolution gel from a successful in-vitro cleavage assay with 100% 
efficiency would have resulted in two bands around the 75 base pair size marker and no band 
present around the 150 base pairs size marker. This would indicate that the entirety of the 
dsDNA substrate had been cleaved into the smaller fragments approximately 78 base pairs in 
size. A quantitative measure of the cleavage efficiency of the sgRNA-Cas9 complex that would 
be employed would be obtaining the intensity values of the bands present for the uncut and cut 
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samples using ImageJ software. The intensity values of the two bands within the cut samples 
should add up to the intensity value of the uncut sample theoretically. The percent of efficiency 
could be determined by dividing the combined intensity value from the cut sample by the 
intensity value from the uncut sample (​Figure 20​). 
 
 
Figure 20.​ The formula for calculating the percent of cleavage achieved using intensity values of 
gel bands from cut and uncut samples from ImageJ software. 
 
The next step of the research process would be to bind an RNA binding drug molecule to 
the sgRNA guide and then remove the excess drug through column purification (​Figure 21​). 
Cisplatin, a chemotherapy drug that is known for its RNA affinity, would be incubated for 
different lengths of time at various concentrations with the sgRNA guide. The solution would 
then be placed into a column and purified to remove the excess Cisplatin in solution. The 




Figure 21.​ Intended protocol for making sgRNA-Cisplatin complex to measure cleavage 
efficiency against unbound sgRNA guide in-vitro cleavage assay results. 
 
The next intended in-vitro cleavage assays would consist of a free-sgRNA assay, a 
sgRNA-Cisplatin assay at a lower concentration, and a sgRNA-Cisplatin complex at a higher 
concentration. The high-resolution gel containing these three assays would be used to determine 
whether small RNA binding drug molecules affect the cleavage efficiency of the CRISPR-Cas9 
system (​Figure 22​). 
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Figure 22. ​Hypothetical of high-resolution gel of an in-vitro assay with: no Cisplatin, 100𝜇M 
Cisplatin, and 200𝜇M Cisplatin. 
  
With increasing concentrations of Cisplatin, and presuming this means more Cisplatin bound to 
the sgRNA guide, the cleavage efficiency will decrease. This is visualized in the hypothetical gel 
above as the band around the 150 base pair marker becomes more intense both qualitatively and 
quantitatively (using ImageJ software to measure intensity values). The higher intensity of this 
150 base pair band indicates that more of the AF1 dsDNA substrate (156 bps) is present and 
uncut by the sgRNA-SpyCas9 complex. While the 150 base pair band increases in intensity, the 
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two cut bands around the 75 base pairs would decrease in intensity (qualitatively and 
quantitatively) as there is a less cut product from the in-vitro cleavage assay.  
The hypothetical results were depicted as such assuming maximum efficiency and no 
errors in the protocol, experimentation, and the predicted effect of the Cisplatin drug on the 
sgRNA-SpyCas9 complex. These hypothetical results reflect the intended methodology and 



















Conclusion/ Future Work 
 
 
The purpose of this thesis and research was to explore possible solutions to the issue of 
overcutting of dsDNA if the CRISPR-Cas9 system was introduced in vivo by targeting the 
sgRNA guide that is used for target recognition. By being able to affect the cutting efficiency, 
researchers and medical professionals could have better control over the editing done in 
organisms which could lead to more specific usages for the CRISPR-Cas9 system such as 
neurological diseases, or even viral defense against viruses such as COVID-19. The essence of 
genome editing and longevity of this technology will need to be focused on further controlling 
the editing done otherwise its full potential will never be reached. This thesis was a minor 
investigation into one way that the CRISPR-Cas9 system could be modulated in vitro but with 
the aspirations of applying this hypothesis to an in vivo system, ultimately.  
My senior thesis was abruptly ended on the account of the COVID-19 pandemic with a 
plethora of experiments left incomplete or not even begun. Reminiscing to the week that the labs 
were shut down, I was confident in saying that the reason for the lack of substantial results from 
the in-vitro cleavage assays was due to the inactivity by the SpyCas9 enzyme. The in-vitro 
cleavage assay was put on halt due to a lack of AF1 dsDNA substrate that was currently being 
purified but based on the multitude of assays that were completed with varying conditions, it led 
me to conclude that the SpyCas9 enzyme was to blame for the lack of results. 
In the future, I would like to be able to finish setting up an effective in-vitro cleavage for 
the CRISPR-Cas9 system, but more importantly, start testing a wide range of RNA binding drugs 
and metal complexes against the sgRNA guide to see if it affects the cutting efficiency. Another 
aspect of this hypothesis that would like to be tested is the actual mechanism of hindrance that 
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these RNA binding drugs and metal complexes utilize. In theory, I believe that these complexes 
could be causing an effect through two main mechanisms: sterically and thermodynamically. The 
drugs and metal complexes could sterically block the SpyCas9 from being able to complex with 
the sgRNA therefore not allowing the SpyCas9 enzyme to target the dsDNA substrate. Based on 
the vast literature surrounding RNA binding drugs, and their effect on RNA structures, I believe 
the drugs and metal complexes could make the sgRNA thermodynamically unstable affecting the 
binding affinity it has with the SpyCas9 enzyme.  This could be tested through bind affinity 
assays and Isothermal Calorimetry (ITC) experiments that would then be used as supplementary 
results to the in-vitro cleavage assays measuring cutting efficiency by quantifying the intensity of 
gel bands to conclude whether this hypothesis is correct or not. 
The CRISPR-Cas9 system is an amazing genome editing tool that needs some more 
refinement before this technology can be used to its full potential. This thesis aimed to make a 
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